BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:olatorepatide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of olatorepatide\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07156500-144@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07156500)
DESCRIPTION:olatorepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 St
 udy of HS-20094 in Patients With T2DM Inadequately Controlled With Diet an
 d Exercise Alone\nEstimated primary completion: 30 March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/olatorepatide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07156500
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156539-144@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07156539)
DESCRIPTION:olatorepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 St
 udy of HS-20094 in Patients With T2DM\nEstimated primary completion: 30 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olatorepati
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7156539
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685808-144@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280121
DTEND;VALUE=DATE:20280122
SUMMARY:olatorepatide: Phase 2 readout est. (NCT07685808)
DESCRIPTION:olatorepatide\, phase 2\, Obesity.\nStudy: Study of Olatorepati
 de in Adult Participants Living With Overweight or Obesity Without Diabete
 s\nEstimated primary completion: 21 January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/olatorepatide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07685808
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830329-144@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:olatorepatide: Phase 2 readout est. (NCT07830329)
DESCRIPTION:olatorepatide\, phase 2\, Obesity.\nStudy: Efficacy and Safety 
 of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidraden
 itis Suppurativa Living With Overweight or Obesity\nEstimated primary comp
 letion: 24 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/olatorepatide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07830329
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896265-144@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07896265)
DESCRIPTION:olatorepatide\, phase 3\, Obesity.\nStudy: Efficacy And Safety 
 of Olatorepatide in Adults With Overweight or Obesity Without Diabetes\nEs
 timated primary completion: 19 December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/olatorepatide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07896265
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
